OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Precision oncology provides opportunities for targeting KRAS-inhibitor resistance
Martin Sattler, Atish Mohanty, Prakash Kulkarni, et al.
Trends in cancer (2022) Vol. 9, Iss. 1, pp. 42-54
Open Access | Times Cited: 28
Martin Sattler, Atish Mohanty, Prakash Kulkarni, et al.
Trends in cancer (2022) Vol. 9, Iss. 1, pp. 42-54
Open Access | Times Cited: 28
Showing 1-25 of 28 citing articles:
Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors
Xiangdong Lv, Xuan Lu, Jin Cao, et al.
Science (2023) Vol. 381, Iss. 6662
Open Access | Times Cited: 45
Xiangdong Lv, Xuan Lu, Jin Cao, et al.
Science (2023) Vol. 381, Iss. 6662
Open Access | Times Cited: 45
Next batter up! Targeting cancers with KRAS-G12D mutations
Mara N. Zeissig, Lauren M. Ashwood, Olga Kondrashova, et al.
Trends in cancer (2023) Vol. 9, Iss. 11, pp. 955-967
Open Access | Times Cited: 43
Mara N. Zeissig, Lauren M. Ashwood, Olga Kondrashova, et al.
Trends in cancer (2023) Vol. 9, Iss. 11, pp. 955-967
Open Access | Times Cited: 43
Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer
Caicun Zhou, Chongyang Li, Libo Luo, et al.
Cancer Cell (2024) Vol. 42, Iss. 7, pp. 1286-1300.e8
Closed Access | Times Cited: 11
Caicun Zhou, Chongyang Li, Libo Luo, et al.
Cancer Cell (2024) Vol. 42, Iss. 7, pp. 1286-1300.e8
Closed Access | Times Cited: 11
The Pan-RAF–MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS–MAPK Pathway with Activity across Diverse RAS- and RAF-Driven Cancers
Meagan B. Ryan, Bradley Quade, Natasha Schenk, et al.
Cancer Discovery (2024) Vol. 14, Iss. 7, pp. 1190-1205
Open Access | Times Cited: 7
Meagan B. Ryan, Bradley Quade, Natasha Schenk, et al.
Cancer Discovery (2024) Vol. 14, Iss. 7, pp. 1190-1205
Open Access | Times Cited: 7
Activity and resistance to KRASG12C inhibitors in non-small cell lung cancer and colorectal cancer
Wei Ye, Lu Xin, Yue Qiao, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 3, pp. 189108-189108
Closed Access | Times Cited: 5
Wei Ye, Lu Xin, Yue Qiao, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 3, pp. 189108-189108
Closed Access | Times Cited: 5
KRASG12D-driven pentose phosphate pathway remodeling imparts a targetable vulnerability synergizing with MRTX1133 for durable remissions in PDAC
Xiangyan Jiang, Tao Wang, Bin Zhao, et al.
Cell Reports Medicine (2025) Vol. 6, Iss. 2, pp. 101966-101966
Open Access
Xiangyan Jiang, Tao Wang, Bin Zhao, et al.
Cell Reports Medicine (2025) Vol. 6, Iss. 2, pp. 101966-101966
Open Access
The expanding role of the receptor tyrosine kinase MET as a therapeutic target in non-small cell lung cancer
Martin Sattler, Ravi Salgia
Cell Reports Medicine (2025), pp. 101983-101983
Open Access
Martin Sattler, Ravi Salgia
Cell Reports Medicine (2025), pp. 101983-101983
Open Access
Potency and selectivity of a novel pan-RAS inhibitor in 3D bioprinted organoid tumor models
Daniela Farias de Nóbrega, Logan C. Eiler, Parmanand Ahirwar, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access
Daniela Farias de Nóbrega, Logan C. Eiler, Parmanand Ahirwar, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access
Direct K-Ras Inhibitors to Treat Cancers: Progress, New Insights, and Approaches to Treat Resistance
Ruth Nussinov, Hyunbum Jang
The Annual Review of Pharmacology and Toxicology (2023) Vol. 64, Iss. 1, pp. 231-253
Closed Access | Times Cited: 12
Ruth Nussinov, Hyunbum Jang
The Annual Review of Pharmacology and Toxicology (2023) Vol. 64, Iss. 1, pp. 231-253
Closed Access | Times Cited: 12
A Closer Look at EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer through the Lens of Precision Medicine
Martin Sattler, Isa Mambetsariev, Jeremy Fricke, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 5, pp. 1936-1936
Open Access | Times Cited: 10
Martin Sattler, Isa Mambetsariev, Jeremy Fricke, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 5, pp. 1936-1936
Open Access | Times Cited: 10
Unravelling the complexities of resistance mechanism in pancreatic cancer: insights from in vitro and ex-vivo model systems
Giulia Lencioni, Alessandro Gregori, Belen Toledo B, et al.
Seminars in Cancer Biology (2024)
Open Access | Times Cited: 3
Giulia Lencioni, Alessandro Gregori, Belen Toledo B, et al.
Seminars in Cancer Biology (2024)
Open Access | Times Cited: 3
Design, Synthesis, and Pharmacological Evaluation of Multisubstituted Pyrido[4,3-d]pyrimidine Analogues Bearing Deuterated Methylene Linkers as Potent KRASG12D Inhibitors
Xuanzheng Xiao, Juanjuan Feng, Jing Ma, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 22, pp. 15524-15549
Closed Access | Times Cited: 7
Xuanzheng Xiao, Juanjuan Feng, Jing Ma, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 22, pp. 15524-15549
Closed Access | Times Cited: 7
The research advances in Kirsten rat sarcoma viral oncogene homolog (KRAS)-related cancer during 2013 to 2022: a scientometric analysis
Yujie Huang, Daitian Zheng, Zhongming Zhou, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
Yujie Huang, Daitian Zheng, Zhongming Zhou, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
PGM3 inhibition shows cooperative effects with erastin inducing pancreatic cancer cell death via activation of the unfolded protein response
Barbara Zerbato, Maximilian Gobbi, Tobias Ludwig, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 3
Barbara Zerbato, Maximilian Gobbi, Tobias Ludwig, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 3
SOS1 inhibition enhances the efficacy of and delays resistance to G12C inhibitors in lung adenocarcinoma
Brianna R. Daley, Nancy E. Sealover, Erin Sheffels, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 3
Brianna R. Daley, Nancy E. Sealover, Erin Sheffels, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 3
Hetero-tricyclic Compounds as KRAS Inhibitors for Treating Cancer
Ram W. Sabnis
ACS Medicinal Chemistry Letters (2023) Vol. 14, Iss. 9, pp. 1154-1155
Open Access | Times Cited: 2
Ram W. Sabnis
ACS Medicinal Chemistry Letters (2023) Vol. 14, Iss. 9, pp. 1154-1155
Open Access | Times Cited: 2
RIT1M90I is a driver of lung adenocarcinoma tumorigenesis and resistance to targeted therapy
Danilo Maddalo, Ashley V. DiMarco, Mirunalini Ravicahndran, et al.
Research Square (Research Square) (2024)
Open Access
Danilo Maddalo, Ashley V. DiMarco, Mirunalini Ravicahndran, et al.
Research Square (Research Square) (2024)
Open Access
Spatial iTME analysis of KRAS mutant NSCLC and immunotherapy outcome
Dan Zhao, Haiqing Li, Isa Mambetsariev, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access
Dan Zhao, Haiqing Li, Isa Mambetsariev, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access
VT204: A Potential Small Molecule Inhibitor Targeting KRASG12C Mutation for Therapeutic Intervention in Non-Small Cell Lung Cancer
Xuechao Yang, Shu Zhang, Yang Yang, et al.
Technology in Cancer Research & Treatment (2024) Vol. 23
Open Access
Xuechao Yang, Shu Zhang, Yang Yang, et al.
Technology in Cancer Research & Treatment (2024) Vol. 23
Open Access
KRAS combination strategies: How well aligned is clinical and preclinical research?
Ernest Nadal, Chiara Ambrogio, David Santamarı́a, et al.
Elsevier eBooks (2024), pp. 417-441
Closed Access
Ernest Nadal, Chiara Ambrogio, David Santamarı́a, et al.
Elsevier eBooks (2024), pp. 417-441
Closed Access
Macropinocytosis-targeted peptide-docetaxel conjugate for bystander pancreatic cancer treatment
Young Seok Cho, Hanhee Cho, Ha Rin Kim, et al.
Journal of Controlled Release (2024) Vol. 376, pp. 829-841
Closed Access
Young Seok Cho, Hanhee Cho, Ha Rin Kim, et al.
Journal of Controlled Release (2024) Vol. 376, pp. 829-841
Closed Access
KRAS inhibitors in drug resistance and potential for combination therapy
Lala S. Rathod, Nikhil S. Sakle, Santosh N. Mokale
Tumori Journal (2024)
Closed Access
Lala S. Rathod, Nikhil S. Sakle, Santosh N. Mokale
Tumori Journal (2024)
Closed Access
A novel HLA Class II presentation prediction algorithm deciphers immunogenic CD4 epitopes specific to KRAS G12C
Daniel J. Sprague, Meghan G. Hart, Joshua S. Klein, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Daniel J. Sprague, Meghan G. Hart, Joshua S. Klein, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Novel Tricyclic Compounds as KRAS Inhibitors for Treating Cancer
Ram W. Sabnis
ACS Medicinal Chemistry Letters (2023) Vol. 14, Iss. 5, pp. 555-556
Open Access | Times Cited: 1
Ram W. Sabnis
ACS Medicinal Chemistry Letters (2023) Vol. 14, Iss. 5, pp. 555-556
Open Access | Times Cited: 1
Novel Quinoline Compounds as KRAS Inhibitors for Treating Cancer
Ram W. Sabnis
ACS Medicinal Chemistry Letters (2023) Vol. 14, Iss. 6, pp. 707-708
Open Access | Times Cited: 1
Ram W. Sabnis
ACS Medicinal Chemistry Letters (2023) Vol. 14, Iss. 6, pp. 707-708
Open Access | Times Cited: 1
